Arca
Skip to content

Sinusitis

Drug research and approvals for sinusitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 23 studies of sinusitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 23
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

21 approved, 12 in phase 3, 13 in phase 2, 12 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Amoxicillin, Levofloxacin anhydrous, Azithromycin, Epinephrine, Dupilumab, Clavulanic acid, Guaifenesin, Moxifloxacin, Telithromycin, Dextromethorphan, Pseudoephedrine, Cefuroxime axetil, Clarithromycin, Ciprofloxacin, Carbetapentane, Chlorpheniramine, Brompheniramine, Phenylephrine, Naphazoline, Oxymetazoline, Cefprozil anhydrous, (e)-

Mometasone furoate
Phase 3 Glucocorticoid receptor agonist
Budesonide
Phase 3 Glucocorticoid receptor agonist
Dornase alfa
Phase 3 DNA hydrolytic enzyme
Fluticasone propionate
Phase 3 Glucocorticoid receptor agonist
Omalizumab
Phase 3 Ig epsilon chain C region inhibitor
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Beclomethasone dipropionate
Phase 3 Glucocorticoid receptor agonist
Reslizumab
Phase 3 Interleukin-5 inhibitor
Prednisone
Phase 3 Glucocorticoid receptor agonist
Rimegepant
Phase 3 Calcitonin gene-related peptide type 1 receptor antagonist
Acetylcysteine
Phase 3 Glutathione precursor
Pranlukast
Phase 3 Cysteinyl leukotriene receptor 1 antagonist
Itraconazole
Phase 2 Cytochrome P450 51 inhibitor
Betamethasone dipropionate
Phase 2 Glucocorticoid receptor agonist
Nitric oxide
Phase 2 Soluble guanylate cyclase activator
Acetaminophen
Phase 2 Cyclooxygenase inhibitor
Ibuprofen
Phase 2 Cyclooxygenase inhibitor
Oxycodone
Phase 2 Mu opioid receptor agonist
Esmolol
Phase 2 Beta-1 adrenergic receptor antagonist
Simvastatin
Phase 2 HMG-CoA reductase inhibitor
Labetalol
Phase 2 Adrenergic receptor antagonist
Benralizumab
Phase 2 Interleukin-5 receptor subunit alpha inhibitor
Etokimab
Phase 2 Interleukin-33 binding agent
Lactobacillus acidophilus
Phase 2 Probiotic
Xylitol
Phase 2
Silver
Phase 1
Bupivacaine
Phase 1 Sodium channel protein type IV alpha subunit blocker
Tobramycin
Phase 1 70S ribosome inhibitor
Vancomycin
Phase 1 Peptidoglycan inhibitor
Mupirocin
Phase 1 Isoleucyl-tRNA synthetase inhibitor

Showing the 30 furthest along of 37 in trials.

How Its Trials Ended

454 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 114 whose ending is known, 41% met their primary endpoint, 6% missed it and 53% stopped early.

  • Completed, result not reported19142%
  • Ongoing9320%
  • Status unknown5612%
  • Met its primary endpoint4710%
  • Stopped: other or unclear347%
  • Stopped: enrollment or feasibility133%
  • Missed its primary endpoint72%
  • Stopped: lack of efficacy61%
  • Stopped: funding41%
  • Stopped: sponsor or business decision31%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.